EFMC-ISMC 2018

Programme Schedule

The Programme is available here!


Follow us!

EFMC-ISMC EFMC-ISMC EFMC-ISMC

Spread the word with #EFMC_ISMC

Confirmed Speakers


Award & Prize Lectures

Prof. Benjamin CRAVATT
Prof. Benjamin CRAVATT
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States

PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY

Prof. Christa MÜLLER
Prof. Christa MÜLLER
UNIVERSITY OF BONN, Bonn, Germany

NAUTA AWARD FOR PHARMACOCHEMISTRY

Prof. Adam NELSON
Prof. Adam NELSON
UNIVERSITY OF LEEDS, Leeds, United Kingdom

UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY

Plenary Lectures


Prof. Tatjana AVSIC-ZUPANC
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia

Title to be announced

Prof. Benjamin DAVIS
Prof. Benjamin DAVIS
OXFORD UNIVERSITY, Oxford, United Kingdom
Read more

Sugars and Proteins

Dr Bayard HUCK
Dr Bayard HUCK
MERCK BIOPHARMA, Darmstadt, Germany
Read more

It’s a Small-Molecule World: Medicinal Chemistry Challenges and Opportunities for the Next Decade

Prof. Cristina NEVADO
Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland

Title to be announced


Dr Helga RÜBSAMEN-SCHAEFF
AICURIS GMBH & CO. KG, Wuppertal, Germany

Development of Non-Nucleosidic Compounds against DNA Viruses of the Herpes Group. The Era After Nucleosides: Letermovir and Pritelivir

Prof. Peter H. SEEBERGER
Prof. Peter H. SEEBERGER
MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany
Read more

Synthetic Glycoconjugate Vaccines against Bacterial Infections

Invited Speakers

Dr Hassan AL-ALI
Dr Hassan AL-ALI
THE MIAMI PROJECT TO CURE PARALYSIS, Miami, United States
Read more

Exploiting Kinase Polypharmacology to Promote Nerve Regeneration

Dr David BERNIER
Dr David BERNIER
BAYER S.A.S. - CROPSCIENCE DIVISION, Lyon, France
Read more

A New Target in Fungal Protein Biosynthesis: Shared Learnings for AgChem and MedChem

Dr Jonas BOSTRÖM
Dr Jonas BOSTRÖM
ASTRAZENECA, Mölndal, Sweden
Read more

Stuck in a Rut with Old Chemistry

Dr Giovanni BOTTEGONI
Dr Giovanni BOTTEGONI
HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom
Read more

In silico Polypolpharmacology

Dr Cedric BOULARAN
Dr Cedric BOULARAN
INVIVOGEN, Toulouse, France
Read more

Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity

Prof. Christina CHAI
Prof. Christina CHAI
NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore
Read more

Towards the Development of Small Molecule Therapy for Chikungunya

Dr Philip CHAMBERLAIN
Dr Philip CHAMBERLAIN
CELGENE, Alameda, United States
Read more

Targeting Transcription and Translation Factors for Degradation with Low Molecular Weight Cereblon Modulators


Prof. Steven CHARLTON
UNIVERSITY OF NOTTINGHAM, Nottingham, United Kingdom

"Micro-Pharmacokinetics”: How Local Drug Concentration Influences Observed Binding Kinetics


Prof. Fener CHEN
FUDAN UNIVERSITY, China

Asymmetric Aldol Reactions of Heterocyclic Dienolsilanes and α,β-Unsaturated Carbonyl Derived Dienolsilanes


Prof. Zhijian CHEN
UNIVERSITY OF TEXAS, Dallas, United States

Innate Immune Sensing and Signaling of Cytosolic DNA

Dr Diane COE
Dr Diane COE
GLAXOSMITHKLINE, Stevenage, United Kingdom
Read more

Modification of Cyclic Dinucleotides to Enhance Modulation of the Innate Immune Response

Dr Liesbeth DE LANGE
Dr Liesbeth DE LANGE
UNIVERSITY OF LEIDEN, Leiden, The Netherlands

Target Binding Kinetics and its Relevance in the in vivo Context

Prof. Bernard FLYNN
Prof. Bernard FLYNN
MONASH UNIVERSITY, Parkville, Australia
Read more

Unravelling the Mysteries of the Sphinx: New Therapeutic Targets and Drug Leads from the Phenotypic Screening of Non-Lipid Sphingolipid Mimetics

Prof. Karl GADEMANN
Prof. Karl GADEMANN
UNIVERSITY OF ZURICH, Zurich, Switzerland
Read more

Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis

Prof. Antony GEE
Prof. Antony GEE
KING'S COLLEGE LONDON, London, United Kingdom
Read more

PET Molecular Imaging – an Overview


Dr Riccardo GIOVANNINI
BOEHRINGER INGELHEIM, Biberach, Germany

First Time Disclosure of BI 409306, a First in Class PDE9 Inhibitor for the Treatment of CNS Diseases

Prof. Stanislav GOBEC
Prof. Stanislav GOBEC
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
Read more

Nonpeptidic Selective Inhibitors of Immunoproteasome

Dr Stephanie GUERET
Dr Stephanie GUERET
ASTRAZENECA-MAX PLANCK INSTITUTE SATELLITE UNIT, Dortmund, Germany
Read more

Novel Hybrid Macrocyclic Modalities for Structure-Based Protein Mimetics

Dr Michael G. HAHN
Dr Michael G. HAHN
BAYER HEALTHCARE, Wuppertal, Germany
Read more

Discovery of a Novel Oral NO- and Haem-Independent sGC Activator BAY 1101042

Dr Laura HEITMAN
Dr Laura HEITMAN
UNIVERSITY OF LEIDEN, Leiden, The Netherlands

Allosteric Modulation of the mGlu2 Receptor: From Structure-Kinetic Relationships to in vivo Efficacy
(2017 MedChemComm Emerging Investigator Lectureship)

Dr Jinbo HU
Dr Jinbo HU
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China
Read more

Sulfur- and Silicon-Based Fluorination Reagents for Medicinal Chemistry

Dr Jesus JIMENEZ-BARBERO
Dr Jesus JIMENEZ-BARBERO
CIC BIOGUNE, Derio, Spain
Read more

Breaking the Limits in Analyzing Carbohydrate Recognition by NMR

Dr Jesper LAU
Dr Jesper LAU
NOVO NORDISK, Maaloev, Denmark
Read more

From Ala Scan to Structural Design of GLP-1 Analogues

Prof. Stefan LAUFER
Prof. Stefan LAUFER
UNIVERSITY OF TÜBINGEN, Tübingen, Germany
Read more

EGFR Triple Mutant - Recent Set-Backs and New Hopes in Fighting Mutant Non-Small Cell Lung Cancer

Dr David E. LEAHY
Dr David E. LEAHY
THE DISCOVERY BUS LTD, Macclesfield, United Kingdom
Read more

Artificial Intelligence. Not Just Another Name for in Silico Design

Dr Mark J. MILLAN
Dr Mark J. MILLAN
INSTITUT DE RECHERCHES SERVIER, Croissy-sur-Seine, France
Read more

Multi-Functional Treatments for Multi-Factorial Neurodegenerative Disorders: the Challenge of Alzheimer's Disease

Dr Laurence MULARD
Dr Laurence MULARD
INSTITUT PASTEUR, Paris, France

Infectious Diseases. Synthesis and Molecular Recognition

Dr Mikihiko NAITO
Dr Mikihiko NAITO
NATIONAL INSTITUTE OF HEALTH SCIENCES, Tokyo, Japan
Read more

Recent Advances in Bifunctional Degrader Molecules (e.g. SNIPER) for Targeted Protein Degradation via the Ubiquitin Proteasome System; Status and Outlook

Prof. Hermen OVERKLEEFT
Prof. Hermen OVERKLEEFT
LEIDEN UNIVERSITY, Leiden, The Netherlands
Read more

Activity-Based Glycosidase Profiling in Biomedicine and Biotechnology

Prof. Roberto PELLICCIARI
Prof. Roberto PELLICCIARI
TES PHARMA SRL, Corciano, Italy
Read more

Obeticholic Acid, Leading in the NASH Race. History and Perspectives

Dr Robert PULZ
Dr Robert PULZ
NOVARTIS PHARMA, Basel, Switzerland
Read more

Discovery of LOU064, a Covalent BTK Inhibitor with Best in Class Selectivity

Dr Laura QUARANTA
Dr Laura QUARANTA
SYNGENTA AG, Basel, Switzerland
Read more

Synthesis and Fungicidal Activity of Novel Inhibitors of Oxysterol Binding Protein

Dr Murali RAMACHANDRA
Dr Murali RAMACHANDRA
AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India
Read more

Small Molecule Immune Checkpoint Antagonists for Cancer Therapy

Dr Hasane RATNI
Dr Hasane RATNI
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
Read more

Discovery of RG7916, a Selective SMN2 Splicing Modifier for the Treatment of Spinal Muscular Atrophy


Dr Joachim RHEINHEIMER
BASF, Ludwigshafen am Rhein, Germany

Natural Products as Leads in Agrochemistry

Dr Raphaël RODRIGUEZ
Dr Raphaël RODRIGUEZ
INSTITUT CURIE, Paris, France
Read more

An Iron Hand over Cancer Stem Cells

Dr Webster L. SANTOS
Dr Webster L. SANTOS
VIRGINIA TECH, Blacksburg, United States
Read more

Controlling Sphingosine-1-Phosphate Levels as a Therapeutic Strategy

Dr Laurent SCHIO
Dr Laurent SCHIO
SANOFI, Vitry sur Seine, France
Read more

From Pan Kinase to (Ultra) Selective Kinase Inhibitors

Dr Magnus SCHOU
Dr Magnus SCHOU
KAROLINSKA INSTITUTE, Stockholm, Sweden
Read more

PET in Neuroscience Drug Discovery and Development


Prof. David SELWOOD
UNIVERSITY COLLEGE LONDON, London, United Kingdom

C-Natruiretic Peptide Agonists for Cardiovascular Disease

Dr Zhang-Jie SHI
Dr Zhang-Jie SHI
FUDAN UNIVERSITY, Shanghai, China
Read more

Direct Transformation of Unreactive Chemical Bonds

Prof. Satoshi SHUTO
Prof. Satoshi SHUTO
HOKKAIDO UNIVERSITY, Sapporo, Japan
Read more

Design and Synthesis of Congerners of Cyclic ADP-Ribose, a Ca2+-Mobilizing Second Messenger, Toward Identification of the Target Protein

Prof. Richard B. SILVERMAN
Prof. Richard B. SILVERMAN
NORTHWESTERN UNIVERSITY, Evanston, United States
Read more

Design, Synthesis, and Mechanism of β-Glucocerebrosidase Activators for Gaucher’s and Parkinson’s Diseases

Prof. Jurij SVETE
Prof. Jurij SVETE
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
Read more

New Chemical Libraries in Exploration of Chemical Space

Dr Nick TERRETT
Dr Nick TERRETT
MERCK SHARP & DOHME RESEARCH GMBH (MSD), Kriens, Switzerland
Read more

Cell Permeability with Beyond ‘Rule of 5’ Modalities – Do We Understand How This Works?

Dr Nicolas THOMÄ
Dr Nicolas THOMÄ
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

The CRBN/IMiD Degrome

Dr Jan Willem THURING
Dr Jan Willem THURING
JANSSEN PHARMACEUTICA NV, Beerse, Belgium
Read more

Discovery of JNJ-64619178 as a Potent and Selective PRMT5 Inhibitor for the Treatment of Lung and Hematologic Cancers

Prof. Matthew TODD
Prof. Matthew TODD
UNIVERSITY OF SYDNEY, Sydney, Australia
Read more

All Bugs are Shallow: Open Source Drug Discovery

Dr Gergely TOTH
Dr Gergely TOTH
CANTABIO PHARMACEUTICALS INC., Sunnyvale, United States
Read more

Targeting the Monomeric Intrinsically Disordered Structural State of Tau and Alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Alzheimer's and Parkinson’s Disease.

Dr Wes TROTTER
Dr Wes TROTTER
MSD, Boston, United States
Read more

Cyclic Dinucleotide STING Agonists as Anti-Tumor Agents

Dr David TULLY
Dr David TULLY
NOVARTIS, Emeryville, United States
Read more

Discovery of LJN452 (Tropifexor), a Highly Potent, Non-Bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and NASH


Dr Sean C. TURNER
ABBVIE, Ludwigshafen am Rhein, Germany

Allosteric Modulators of the GABA-B Receptor

Dr Anne VALADE
Dr Anne VALADE
UCB, Braine-l'Alleud, Belgium
Read more

The Value of Orthogonal Techniques for Elucidating Binding Site(s) of GPCR Allosteric Modulators: a Case Study With Positive Allosteric Modulators of Dopamine Receptors

Dr Eric VALEUR
Dr Eric VALEUR
ASTRAZENECA, IMED BIOTECH UNIT, Gothenburg, Sweden
Read more

New Modalities for Complex and Unprecedented Biological Targets

Dr Willem VAN HOORN
Dr Willem VAN HOORN
EXSCIENTIA, Dundee, United Kingdom
Read more

Re-Energising Small Molecule Drug Discovery


Prof. Hans WANDALL
UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark

Targeting of Cancer Specific Glycopeptide Epitopes

Dr Sven WEILER
Dr Sven WEILER
BASILEA PHARMACEUTICA INTERNATIONAL LTD., Basel, Switzerland
Read more

Active Site Inhibitors of Sphingosine 1-Phosphate Lyase? Exploring Novel Biology with Tool Compounds


Prof. Bert WINDHORST
VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands

PET for Oncology Drug Discovery and Development

Dr Wolfgang WRASIDLO
Dr Wolfgang WRASIDLO
UNIVERSITY OF CALIFORNIA SAN DIEGO, La Jolla, United States
Read more

Discovery of Peptidomimetics Targeting Protein-Protein Interactions of Alpha-Synuclein

Prof. Hang YIN
Prof. Hang YIN
TSINGHUA UNIVERSITY, Beijing, China
Read more

Small-Molecule Immunomodulators that Target Toll-Like Receptors

Prof. Xumu ZHANG
Prof. Xumu ZHANG
SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY, Guangdong, China
Read more

Practical Asymmetric Hydrogenation

Prof. Markus ZWECKSTETTER
Prof. Markus ZWECKSTETTER
MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany
Read more

Understanding Aggregation Inhibition of Alpha-Synuclein and Tau by Small Molecules

Oral Communications

Dr Amjad ALI
Dr Amjad ALI
MERCK, SHARP & DOHME, Kenilworth, United States

Discovery and Clinical Evaluation of MK-8150, a Novel Nitric Oxide Donor with a Unique Mechanism of Nitric Oxide Release

Dr Steve ANDREWS
Dr Steve ANDREWS
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

Brain-Penetrant Autophagy Modulators for Treating Neurodegenerative Diseases

Dr Bernard BARLAAM
Dr Bernard BARLAAM
ASTRAZENECA, Cambridge, United Kingdom
Read more

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 that Enables Transient Target Engagement for the Treatment of Haematological Malignancies

Dr Stefan BÄURLE
Dr Stefan BÄURLE
BAYER AG, Berlin, Germany
Read more

First Disclosure of the Clinical Candidate BAY-840, a Potent And Selective hBradykinin B1 Antagonist for the Treatment of Chronic Inflammatory Diseases, Generated within the Bayer-Evotec Strategic Alliance

Dr Jose CID
Dr Jose CID
JANSSEN R&D, Toledo, Spain
Read more

Metabotropic Glutamate Receptor Type 2 Positive Allosteric Modulators (mGlu2 Receptor PAMS) as a Transformational Epilepsy Treatment

Prof. Gabriele COSTANTINO
Prof. Gabriele COSTANTINO
UNIVERSITY OF PARMA, Parma, Italy

Targeting Non Essential Bacterial Targets as a Novel Route to Counteract Bacterial Resistance


Dr Vincent DARMENCY
AC IMMUNE SA, Lausanne, Switzerland

Discovery of Candidates for PET Molecular Imaging of Pathological TDP-43 Aggregates in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Patients

Ms Ana Rita DE CARVALHO ACURCIO
Ms Ana Rita DE CARVALHO ACURCIO
UNIVERSITY OF LISBON, Lisbon, Portugal
Read more

New Small-Molecule Immune Checkpoint Inhibitors: A Step Forward in Cancer Immunotherapy

Dr Al DOSSETTER
Dr Al DOSSETTER
MEDCHEMICA LIMITED, Macclesfield, United Kingdom
Read more

Potency and Patents, New Arenas for Matched Molecular Pair Analysis in the AI World

Prof. Maria DUCA
Prof. Maria DUCA
UNIVERSITÉ CÔTE D'AZUR, Nice, France
Read more

Synthetic Small-Molecule RNA Ligands: Scope and Therapeutic Applications

Dr Peter ETTMAYER
Dr Peter ETTMAYER
BOEHRINGER-INGELHEIM, Vienna, Austria
Read more

Chemical Probes for New Therapeutic Concept Discovery

Dr Esther FERNANDEZ
Dr Esther FERNANDEZ
GLAXOSMITHKLINE, Tres Cantos, Spain
Read more

Identification of New Antimalarial GSK607: An Example of Adaptive and Differentiated Early Drug Development

Prof. Paul FISH
Prof. Paul FISH
ARUK UCL DRUG DISCOVERY INSTITUTE, London, United Kingdom
Read more

Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signaling for the Maintainance of Synaptic Function in Alzheimer’s Disease

Dr Carles GALDEANO
Dr Carles GALDEANO
UNIVERSITY OF BARCELONA, Barcelona, Spain
Read more

Drugging the Fbw7 E3 Ligase with a Combined Computational and Biophysical Approach

Dr Matthias GEHRINGER
Dr Matthias GEHRINGER
UNIVERSITY OF TUEBINGEN, Tuebingen, Germany
Read more

Buruli Ulcer and the mTOR Pathway: Total Synthesis, Structure-Activity and Target Elucidation Studies of Mycolactones

Ms Victoria GEORGI
Ms Victoria GEORGI
BAYER AG, Berlin, Germany
Read more

Large-Scale Analysis of Kinase Inhibitors Target Binding Kinetics and its Implications for Drug Discovery


Dr Brian GERSTENBERGER
PFIZER, Cambridge, United States

Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn’s Disease, and Other Autoimmune Conditions

Prof. Antimo GIOIELLO
Prof. Antimo GIOIELLO
UNIVERSITY OF PERUGIA, Perugia, Italy
Read more

Integrated System for the Expedited Generation and Characterization of Drug-Like Libraries for Hit-To-Lead Explorations


Dr Peter GROOTENHUIS
VERTEX PHARMACEUTICALS, San Diego, United States

IUPAC-Richter Prize Lecture


Dr Steven HOWARD
ASTEX THERAPEUTICS , Cambridge , United Kingdom

ASTX660, the First Fragment-Derived IAP Antagonist in the Clinic

Prof. James JANETKA
Prof. James JANETKA
WASHINGTON UNIVERSITY IN SAINT LOUIS, Saint Louis, United States
Read more

Glycoside Antagonists of Bacterial Lectins: New Treatment Options for Recurrent and Antibiotic Resistant UTI

Dr Allan JORDAN
Dr Allan JORDAN
CANCER RESEARCH UK MANCHESTER INSTITUTE, Manchester, United Kingdom
Read more

Discovery of First-In-Class, Selective and Noncovalent Small Molecule Inhibitors of DNMT1

Dr Jamie KNIGHT
Dr Jamie KNIGHT
CHARLES RIVER, Harlow, United Kingdom
Read more

Discovery of GDC-0077: A Highly Selective Inhibitor and Degrader of Mutant PI3K-Alpha


Dr Rainer MACHAUER
NOVARTIS PHARMA AG, Basel, Switzerland
Read more

The Discovery of CNP520, an Amino-1,4-Oxazine BACE Inhibitor in Prevention Studies

Dr Daniel MERK
Dr Daniel MERK
ETH ZÜRICH, Zürich, Switzerland
Read more

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Treat Non-Alcoholic Steatohepatitis
(EFMC-YMCS Presentation Prize)

Ms Anna MIGGLAUTSCH
Ms Anna MIGGLAUTSCH
TU GRAZ, Graz, Austria
Read more

Development of Small-Molecule Inhibitors of Adipose Triglyceride Lipase (ATGL)

Mr Andrew MONTGOMERY
Mr Andrew MONTGOMERY
UNIVERSITY OF WOLLONGONG, Wollongong, Australia
Read more

Development of Novel Sialyltransferase Inhibitors via Computer Aided Drug Design

Dr Christian OTTMANN
Dr Christian OTTMANN
EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands

Small-Molecule Stabilization of Protein-Protein Interactions by Natural Products, Supramolecular Ligands, Fragments and Macrocycles

Dr Vladimir A. PALYULIN
Dr Vladimir A. PALYULIN
LOMONOSOV MOSCOW STATE UNIVERSITY, Moscow, Russia
Read more

AMPA Receptor Positive Allosteric Modulators Based on New Scaffolds: Design, Synthesis, and Studies

Mr Tamas REVESZ
Mr Tamas REVESZ
BIOLOGICAL RESEARCH CENTRE, HUNGARIAN ACADEMY OF SCIENCES, Szeged, Hungary
Read more

Charting the Structure-Resistance Landscape of Novel Antibiotics

Dr Shabnam SHAABANI
Dr Shabnam SHAABANI
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
Read more

Small Molecules Inhibiting PD1-PDL1 Immune Checkpoint

Dr Hong SHEN
Dr Hong SHEN
ROCHE INNOVATION CENTER, Shanghai, China
Read more

Anti-HBV Drug Discovery Enabled by Structure-Based Drug Design and Phenotypic Screening

Dr Alice SOSIC
Dr Alice SOSIC
UNIVERSITY OF PADOVA, Padova, Italy
Read more

Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Small Molecules Targeting RNA

Dr Hauke SZILLAT
Dr Hauke SZILLAT
SANOFI, Frankfurt, Germany
Read more

Discovery and Optimization of Non-Covalent, Selective, and Bioavailable Small Molecule Inhibitors of the KEAP1-Nrf2 Pathway

Dr Juraj VELCICKY
Dr Juraj VELCICKY
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

Discovery of SPL-707: a Potent, Selective, and Orally Bioavailable SPPL2a Inhibitor

Dr Fredrik ZETTERBERG
Dr Fredrik ZETTERBERG
GALECTO BIOTECH, Gothenburg, Sweden
Read more

The First Class of Orally Available Mono-Saccharide Galectin-3 Inhibitors for Treatment of Fibrosis (NASH) and Cancer


Gold Sponsors

Silver Sponsors

Bronze Sponsors

Award & Prize Sponsors

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys